1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 製品タイプ別スニペット
3.2. 動物タイプ別スニペット
3.3. 投与経路別スニペット
3.4. エンドユーザー別スニペット
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 人獣共通感染症の増加
4.1.1.2. 抗生物質製剤の技術的進歩
4.1.2. 阻害要因
4.1.2.1. 厳しい規制
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 特許分析
5.6. PESTLE分析
5.7. SWOT分析
5.8. DMI意見
6. 製品タイプ別
6.1. 製品紹介
6.1.1. 製品タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（製品タイプ別
6.2. 抗寄生虫*製品
6.2.1. 製品紹介
6.3. 抗菌
6.4. 非ステロイド性抗炎症薬
6.5. その他
7. 動物タイプ別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）、動物タイプ別
7.2. 市場魅力度指数（動物タイプ別
7.3. コンパニオンアニマル*市場
7.3.1. はじめに
7.3.2. 市場規模分析と前年比成長率分析(%)
7.4. 畜産動物
8. 投与経路別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）、投与経路別
8.1.2. 市場魅力度指数（投与経路別
8.2. 経口*剤
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. インジェクション
8.4. 外用剤
8.5. その他
9. エンドユーザー別
9.1. 導入
9.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
9.1.2. 市場魅力度指数、エンドユーザー別
9.2. 動物病院
9.2.1. はじめに
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 動物病院
9.4. その他
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
10.2.4. 市場規模分析およびYoY成長率分析（%）、動物タイプ別
10.2.5. 市場規模分析および前年比成長率分析（%）, 投与経路別
10.2.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.2.7. 市場規模分析および前年比成長率分析（%）, 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
10.3.4. 市場規模分析およびYoY成長率分析（%）、動物タイプ別
10.3.5. 市場規模分析および前年比成長率分析（%）, 投与経路別
10.3.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.3.7. 市場規模分析および前年比成長率分析（%）, 国別
10.3.7.1. ドイツ
10.3.7.2. イギリス
10.3.7.3. フランス
10.3.7.4. イタリア
10.3.7.5. スペイン
10.3.7.6. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
10.4.4. 市場規模分析およびYoY成長率分析（%）、動物タイプ別
10.4.5. 市場規模分析および前年比成長率分析（%）, 投与経路別
10.4.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.4.7. 市場規模分析および前年比成長率分析（%）, 国別
10.4.7.1. ブラジル
10.4.7.2. アルゼンチン
10.4.7.3. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
10.5.4. 市場規模分析およびYoY成長率分析（%）、動物タイプ別
10.5.5. 市場規模分析および前年比成長率分析（%）, 投与経路別
10.5.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.5.7. 市場規模分析および前年比成長率分析（%）, 国別
10.5.7.1. 中国
10.5.7.2. インド
10.5.7.3. 日本
10.5.7.4. 韓国
10.5.7.5. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
10.6.4. 市場規模分析およびYoY成長率分析（%）、動物タイプ別
10.6.5. 市場規模分析および前年比成長率分析（%）, 投与経路別
10.6.6. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11. 競合情勢
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Bayer AG*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. Boehringer Ingelheim GmbH
12.3. Ceva Sante Animale S.A.
12.4. Dechra Pharmaceuticals PLC
12.5. Elanco Animal Health (Eli Lilly Company)
12.6. Merck & Co. Inc
12.7. Sanofi S.A
12.8. Vetoquinol S.A
12.9. Virbac SA
12.10. Zoetis, Inc (*リストは除く)
13. 付録
13.1. 会社概要とサービス
13.2. お問い合わせ

Report Overview
Global Veterinary Antibiotics Market reached US$ 1.5 billion in 2023 and is expected to reach US$ 2.2 billion by 2031, growing at a CAGR of 4.5% during the forecast period 2024-2031.

Veterinary antibiotics are crucial in animal healthcare for treating and preventing infections caused by bacteria, parasites, and other pathogens. They promote livestock health and productivity, ensuring food safety. They are sometimes administered to groups to prevent disease spread in farming environments. However, overuse of antibiotics has raised concerns about antimicrobial resistance, leading to stricter regulations and a focus on responsible antibiotic usage in the veterinary field.

Market Dynamics: Drivers & Restraints
Rise in the prevalence of zoonotic diseases
The global veterinary antibiotics market is experiencing a surge due to the increasing prevalence of zoonotic diseases, which are transmitted from animals to humans. These diseases pose risks to animal health and public health, leading to a greater focus on preventing and controlling infections in livestock and companion animals. Veterinary antibiotics play a crucial role in managing these infections, minimizing transmission to humans, and ensuring food safety by preventing outbreaks in farm animals. This growing concern has led to increased demand for preventive and therapeutic treatments, fueling the global veterinary antibiotics market.
For instance, according to NCBI, in 2023, Zoonotic diseases are responsible for 2.5 billion human cases globally and approximately 2.7 billion deaths annually. Surveillance of animal handlers and livestock for zoonotic pathogens contributes to understanding the true disease burden and risk factors within a community.

Stringent Regulations
The global veterinary antibiotics market faces challenges due to overuse, stricter regulations, increased demand for antibiotic-free food, and the wider application of disease reduction methods, which are exacerbated by growing concerns over antibiotic overuse.

Market Segment Analysis
The global veterinary antibiotics market is segmented based on product type, animal type, route of administration, end user, and region.
The anti-bacterial from the product type segment accounted for approximately 41.3% of the veterinary antibiotics market share
The anti-bacterial from the product type segment accounted for approximately 41.3%. Anti-bacterial agents are vital in the global veterinary antibiotics market, preventing and treating bacterial infections in livestock and companion animals. They improve health and economic outcomes by preventing diseases that could spread rapidly. In the livestock industry, these agents ensure healthier animals, increased productivity, and better food safety.
However, antibiotic resistance has led to stricter regulations and the development of more targeted solutions to reduce excessive usage while maintaining effectiveness. This is shaping the market's future, with innovations focusing on safer, more sustainable antibacterial approaches.
For instance, in February 2024, - Blacksmith Medicines, Inc, a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced a collaboration to discover and develop novel antibiotics for animal health.

Market Geographical Analysis
North America is estimated to hold about 41.04% of the total market share hroughout the forecast period
North America is estimated to hold about 41.04% of the total market share throughout the forecast period due to FDA approvals, rising requirement for antibiotics in veterinary treatments & surgeries, disease prevention, control of disease outbreaks to reduce the severity of disease in animals, and the increasing number of animal healthcare centers & practitioners.
For instance, in October 2023 the FDA has approved bedinvetmab injection and Oclacitinib chewable tablets for dogs to control pain associated with osteoarthritis and pruritus. Bedinvetmab is the first monoclonal antibody (mAb) approved for use in dogs, while Oclacitinib is the first chewable treatment for allergic itch and inflammation in dogs aged 1 year or older. Both veterinary drugs are now available for prescription by veterinarians in the US.

Market Segmentation
By Product Type
Anti-parasitic
Anti-bacterial
Non-steroidal anti-inflammatory Drug
Others
By Animal Type
Companion Animals
Livestock Animals
By Route of Administration
Oral
Injection
Topical
Others
By End User
Veterinary Clinics
Veterinary Hospitals
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape
The major global players in the market include Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Dechra Pharmaceuticals PLC, Elanco Animal Health (Eli Lilly Company), Merck & Co. Inc, Sanofi S.A, Vetoquinol S.A, Virbac SA, Zoetis, Inc among others.

Key Developments
In April 2024, the U.S. Food and Drug Administration approved Pradalex (pradofloxacin injection) solution for certain respiratory diseases in cattle and swine. Pradofloxacin is a medically important antimicrobial in the fluoroquinolone class and may only be prescribed by a licensed veterinarian as a single injection.

Why Purchase the Report?
To visualize the global veterinary antibiotics
Market Segmentation based on product type, animal type, route of administration, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the veterinary antibiotics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global veterinary antibiotics market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Animal Type
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of zoonotic diseases
4.1.1.2. Technological advancements in antibiotic formulations
4.1.2. Restraints
4.1.2.1. Stringent Regulations
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Anti-parasitic*
6.2.1. Introduction
6.3. Anti-bacterial
6.4. Non-Steroidal Anti-inflammatory Drug
6.5. Others
7. By Animal Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
7.2. Market Attractiveness Index, By Animal Type
7.3. Companion Animals*
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Livestock Animals
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Injection
8.4. Topical
8.5. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Veterinary Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Veterinary Hospitals
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Bayer AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Boehringer Ingelheim GmbH
12.3. Ceva Sante Animale S.A.
12.4. Dechra Pharmaceuticals PLC
12.5. Elanco Animal Health (Eli Lilly Company)
12.6. Merck & Co. Inc
12.7. Sanofi S.A
12.8. Vetoquinol S.A
12.9. Virbac SA
12.10. Zoetis, Inc (*LIST NOT EXHAUSTIVE )
13. Appendix
13.1. About Us and Services
13.2. Contact Us

❖ 世界の動物用抗生物質市場に関するよくある質問(FAQ) ❖

・動物用抗生物質の世界市場規模は？
→DataM Intelligence社は2023年の動物用抗生物質の世界市場規模を15億米ドルと推定しています。

・動物用抗生物質の世界市場予測は？
→DataM Intelligence社は2031年の動物用抗生物質の世界市場規模を22億米ドルと予測しています。

・動物用抗生物質市場の成長率は？
→DataM Intelligence社は動物用抗生物質の世界市場が2024年～2031年に年平均4.5%成長すると予測しています。

・世界の動物用抗生物質市場における主要企業は？
→DataM Intelligence社は「Bayer AG、Boehringer Ingelheim GmbH、Ceva Sante Animale S.A.、Dechra Pharmaceuticals PLC、Elanco Animal Health（Eli Lilly Company）、Merck & Co. Inc、Sanofi S.A、Vetoquinol S.A、Virbac SA、Zoetis, Incなど ...」をグローバル動物用抗生物質市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。